Fight against cancer : our therapeutic responses | Pierre Fabre
Pierre Fabre étend ses droits sur le Nerlynx de Puma Biotechnology
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
Fight against cancer : our therapeutic responses | Pierre Fabre
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
THE FACES OF BREAST CANCER
Puma Biotechnology | Evaluate
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Blue March: Pierre Fabre supports colorectal cancer awareness month
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma and CANBridge cancel licensing deal for $20m
Pierre Fabre pens oncology pact with atomic energy spinout | Fierce Biotech
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma licences breast cancer therapy Nerlynx to Pierre Fabre in Europe
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Pierre Fabre & NERLYNX commercialisation | Nerlynx
Accord entre Pierre Fabre et Puma Biotechnology
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Partners of the Pierre Fabre Group: from health to beauty
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
